I-Mab
NASDAQ:IMAB

Watchlist Manager
I-Mab Logo
I-Mab
NASDAQ:IMAB
Watchlist
Price: 0.9397 USD -2.01% Market Closed
Market Cap: 76m USD
Have any thoughts about
I-Mab?
Write Note

I-Mab
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

I-Mab
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
I-Mab
NASDAQ:IMAB
Total Liabilities & Equity
ÂĄ2.6B
CAGR 3-Years
-26%
CAGR 5-Years
2%
CAGR 10-Years
N/A
Beigene Ltd
HKEX:6160
Total Liabilities & Equity
ÂĄ41.1B
CAGR 3-Years
4%
CAGR 5-Years
22%
CAGR 10-Years
N/A
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SSE:603392
Total Liabilities & Equity
ÂĄ15.7B
CAGR 3-Years
65%
CAGR 5-Years
54%
CAGR 10-Years
N/A
Shanghai RAAS Blood Products Co Ltd
SZSE:002252
Total Liabilities & Equity
ÂĄ32.4B
CAGR 3-Years
7%
CAGR 5-Years
23%
CAGR 10-Years
23%
Chongqing Zhifei Biological Products Co Ltd
SZSE:300122
Total Liabilities & Equity
ÂĄ54.8B
CAGR 3-Years
32%
CAGR 5-Years
43%
CAGR 10-Years
36%
Imeik Technology Development Co Ltd
SZSE:300896
Total Liabilities & Equity
ÂĄ6.9B
CAGR 3-Years
14%
CAGR 5-Years
71%
CAGR 10-Years
N/A
No Stocks Found

I-Mab
Glance View

Market Cap
76m USD
Industry
Biotechnology

I-Mab operates as a clinical stage biopharmaceutical company. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-01-17.

IMAB Intrinsic Value
0.7454 USD
Overvaluation 21%
Intrinsic Value
Price

See Also

What is I-Mab's Total Liabilities & Equity?
Total Liabilities & Equity
2.6B CNY

Based on the financial report for Dec 31, 2023, I-Mab's Total Liabilities & Equity amounts to 2.6B CNY.

What is I-Mab's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
2%

Over the last year, the Total Liabilities & Equity growth was -36%. The average annual Total Liabilities & Equity growth rates for I-Mab have been -26% over the past three years , 2% over the past five years .

Back to Top